New data do not SUPPORT triple RAAS blockade

Jan Danser; Ton van den Meiracker

doi:10.1083/nrneph.2015.30

New data do not SUPPORT triple RAAS blockade

Jan Danser, Ton van den Meiracker

Internal Medicine

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

Abstract

The SUPPORT trial evaluated the effect of adding the angiotensin-receptor blocker olmesartan to a combination of angiotensin-converting-enzyme inhibitors and beta-blockers in hypertensive patients with chronic stable heart failure. Unfortunately, this triple renin-angiotensin-aldosterone system blockade was associated with worsening of renal function and increases in cardiac events and mortality.

Original language	Undefined/Unknown
Pages (from-to)	260-261
Number of pages	2
Journal	Nature Reviews Nephrology
Volume	11
Issue number	5
DOIs	https://doi.org/10.1083/nrneph.2015.30
Publication status	Published - 2015

Access to Document

10.1083/nrneph.2015.30

Cite this

@article{586c6821ee2840b5a4368d1da170a8bc,

title = "New data do not SUPPORT triple RAAS blockade",

abstract = "The SUPPORT trial evaluated the effect of adding the angiotensin-receptor blocker olmesartan to a combination of angiotensin-converting-enzyme inhibitors and beta-blockers in hypertensive patients with chronic stable heart failure. Unfortunately, this triple renin-angiotensin-aldosterone system blockade was associated with worsening of renal function and increases in cardiac events and mortality.",

author = "Jan Danser and {van den Meiracker}, Ton",

year = "2015",

doi = "10.1083/nrneph.2015.30",

language = "Undefined/Unknown",

volume = "11",

pages = "260--261",

journal = "Nature Reviews Nephrology",

issn = "1759-5061",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - New data do not SUPPORT triple RAAS blockade

AU - Danser, Jan

AU - van den Meiracker, Ton

PY - 2015

Y1 - 2015

N2 - The SUPPORT trial evaluated the effect of adding the angiotensin-receptor blocker olmesartan to a combination of angiotensin-converting-enzyme inhibitors and beta-blockers in hypertensive patients with chronic stable heart failure. Unfortunately, this triple renin-angiotensin-aldosterone system blockade was associated with worsening of renal function and increases in cardiac events and mortality.

AB - The SUPPORT trial evaluated the effect of adding the angiotensin-receptor blocker olmesartan to a combination of angiotensin-converting-enzyme inhibitors and beta-blockers in hypertensive patients with chronic stable heart failure. Unfortunately, this triple renin-angiotensin-aldosterone system blockade was associated with worsening of renal function and increases in cardiac events and mortality.

U2 - 10.1083/nrneph.2015.30

DO - 10.1083/nrneph.2015.30

M3 - Article

SN - 1759-5061

VL - 11

SP - 260

EP - 261

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

IS - 5

ER -